Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD
NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS,
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026 and is actively
Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance, as
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., ("Galectin" or the "Company") (NASDAQ:GALT) investors that the firm has initiated an investigation
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ:GALT). Such investors are advised
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ:GALT). Such investors are advised
